U.S. government extends RFP-2 contract with Bavarian Nordic

The U.S. government has extended the RFP-2 contract that was awarded to Bavarian Nordic in 2004. Within the scope of the extension, Bavarian Nordic will initiate a larger Phase II study with IMVAMUNE® in people diagnosed with atopic dermatitis. The contract extension has a value of USD 15 million.

 

The additional clinical studies will be performed within the contract period, which has been extended until 2010. However the main part of the revenue is expected in the end of 2008 and beginning of 2009.

 

Anders Hedegaard, President & CEO of Bavarian Nordic, said:"We are very pleased that the U.S. government has decided to extend the ongoing RFP-2 contract to include clinical studies in people with atopic dermatitis, one of the potentially largest risk groups associated with traditional smallpox vaccines. This is an important step in our efforts to develop a safe third-generation smallpox vaccine for the entire population and it builds further on our long-term partnership with the U.S. government."



Asger Aamund

Chairman



Contacts:

 

Anders Hedegaard, President & CEO
Telephone: +45 33 26 83 83

Media: United Kingdom                   

Mary Clark, Capital MS&L   

Telephone: +44 207 307 5330

 

Elizabeth Dempsey Becker, Bavarian Nordic Inc.

Telephone: +1 202 536-1576